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ABSTRACT 
The aim of the present study was to prepare sustained release matrix tablets of lornoxicam to make drug in sustained form so as to 
prolong its elimination time for the effective treatment of rheumatoid arthritis, and also in the management of ankylosing spondylitis, 
acute sciatica and low back pain. The present investigation demonstrates that, use of hydrophilic and hydrophobic polymers could be 
successfully employed for formulating sustained release matrix tablets of Lornoxicam. Optimized formulation containing HPMC 
K100M and Ethyl cellulose at optimum ratio had successfully sustained the drug release for 24 h. Matrix tablets of optimized batch 
had in vitro drug release. It was observed that the optimized matrix tablets of optimized batch shows better flow property by 
studying various pre-compression parameters. Thus, sustained release matrix tablets of Lornoxicam using biocompatible polymers 
were successfully formulated, evaluated and found to be suitable candidates in extending the release of the drug from the matrix 
tablets. 
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INTRODUCTION 
A sustained-release dosage form is defined as “any drug 
or dosage form modification that prolongs the 
therapeutic activity of the drug” 1. Development of oral 
sustained release (SR) tablets of highly water soluble 
drugs or bioactives has always been a challenge and 
therefore, opportunity for formulation scientist. Most of 
these drugs if not formulated properly, may be released 
at a faster rate resulting in exceeding the maximum 
therapeutic levels and hence will lead to toxic side 
effects. Sustained delivery of such drugs ensures 
improved drug delivery and patient compliance, greater 
safety and efficacy, desired release kinetics and helps in 
maintaining the plasma drug concentration within the 
therapeutic window for extended period of time 
2, 3. 
Several techniques including melt granulation 
4
, melt 
pelletization 
5
, hot melt coating 
6
 , Wet granulation 
7, 8, 9
, 
hot melt extrusion 
10
 and direct compression
 11, 12
 have 
been used to obtain sustained release matrix dosage 
forms. 
The tablet can be developed with the combination of 
HPMC K 100M and Ethyl Cellulose as a matrix former. 
Lornoxicam is NSAID that has numerous functions in 
the body. It can be absorbed rapidly and completely 
from gastrointestinal track after the oral administration. 
Absolute bioavailability of Lornoxicam is 90-100%. No 
first pass effect is observed. It is found in the plasma in 
the unchanged form and as its hydroxylated metabolite. 
The hydroxylated metabolite exhibits no 
pharmacological activity. CYP2C3 has been shown to be 
the primary enzyme responsible for the 
biotransformation of Lornoxicam. Approximately 2/3 
part of Lornoxicam is eliminated via the liver and 1/3 
via the kidneys as inactive substance. Lornoxicam 
inhibits the production of prostaglandins by inhibiting 
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the action of cyclooxygenase, which regulates the 
conversion of Arachidonic Acid to Prostaglandins. 
Lornoxicam mainly prescribed in the treatment of 
osteoarthritis and rheumatoid arthritis, and also in the 
management of ankylosing spondylitis, acute sciatica 
and low back pain
13, 14, 15, 16
. 
The main objectives of present investigation are to 
confirm the drug by various analytical techniques, to 
study the drug excipients compatibility, to avoid the 
dose as well as the frequency of the dosage form and to 
perform the stability
13, 14, 15, 16
. 
MATERIALS AND METHODS 
Chemicals: Lornoxicam, HPMC K 100M, Ethyl 
Cellulose, PVP K- 30, Microcrystalline Cellulose, 
Lactose, Talc, Magnesiun Stearate, Potassium 
Dihydrogen Phosphate, Potassium Chloride, Potassium 
Bromide 
Instruments: Electronic Balance, Hot Air Oven, UV 
Spectrophotometer, FTIR Spectrophotometer, DSC, 
Sonicator, Stability Chamber, Tablet Dissolution Testing 
Apparatus, Rimek Mini Tablet Press 2, Monsanto 
Hardness Tester, Rotatory Flask Shaker. 
Preformulation work 
Identification of drug was done by FTIR 
Spectrophotometer and all the drug excipients 
compatibility study was performed. All the ingredients 
were mixed well in a double cone blender. Lornoxicam 
was first mixed with the polymer, PVP K30 and directly 
compressible lactose for 10 min to obtain uniform 
mixture. Then the mixture was passed through 60#. 
Finally the mixture was blended with the talc and 
magnesium stearate. 100 mg tablets were punched by 
compression machine. 
In-process evaluation study
17, 18
 
Pre-compression parameters 
To find out physiochemical properties and release 
characteristics of the granular blend, all formulations are 
subjected to pre-formulation studies like bulk density, 
tapped density, Angle of repose, compressibility index 
and Hausner’s ratio. 
Preparation of matrix tablet: 
Tablets are prepared by direct compression technique
 11, 
12, 19 
 
Table 1: Composition for sustained release matrix tablet of Lornoxicam formulation design 
Ingredients (in mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Lornoxicam 16 16 16 16 16 16 16 16 16 
HPMC K100M 16 32 48 - - - 24 16 08 
Ethyl cellulose - - - 16 32 48 08 16 24 
PVP K 30 10 10 10 10 10 10 10 10 10 
Lactose 40 28 16 56 24 16 32 40 24 
Micro crystalline cellulose 16 12 08 - 16 08 08 - 16 
Magnesium stearate 1 1 1 1 1 1 1 1 1 
Talc 1 1 1 1 1 1 1 1 1 
Total 100 100 100 100 100 100 100 100 100 
 
Evaluation of compressed tablets 
The tablets prepared were evaluated for weight 
variation, disintegration test, dissolution test, thickness, 
hardness of individual dose and friability. 
Weight variation  
The weight variation was performed by weighing 20 
tablets individually, then individual weight of tablet is 
compared with average weight of 20 tablets. 
Hardness 
The hardness of each batch of tablet was checked by 
using Monsanto hardness tester. The hardness was 
measured in terms of kg/cm2.  
Friability  
The friability was determined by first weighing 10 
tablets before placing in friability tester (Roche 
friabilator), which was rotated for 4 min at 25 rpm. After 
dusting, the remaining weight of tablet was determined. 
Thickness 
The thickness of tablet was determined by vernier 
caliper. 
Disintegration
17, 18
 
The test was performed by introducing one tablet in each 
tube and adds a disc to each tube. Suspend the assembly 
in the beaker containing purified water and operate the 
apparatus until the tablet completely disintegrates. 
In Vitro Dissolution test
17, 18
 
In-vitro dissolution studies were carried out using USP 
XXIII dissolution apparatus type II at 50 rpm. 
Dissolution test was carried out for a total period of 24 
hr using 0.1N HCl (pH 1.2) solution (900 ml) as a 
dissolution medium at 37 ± 0. 5
º
C for first 2 hr and 
phosphate buffer (pH 6.8) solution (900 ml) solution for 
the rest of the period.5 ml of sample was withdrawn at 
predetermined time interval of 1 hr up to 24 hr and 
replaced with same volume of fresh dissolution medium. 
The withdrawn samples were filtered and analyzed by 
UV spectrophotometer at 376 nm using pH 6.8 as a 
blank. Percentage cumulative drug release was 
calculated.
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RESULTS AND DISCUSSION 
Pre-compression parameters 
Table 2: Evaluation parameters of powder blend 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 
Loose bulk density 
(LBD) g/ml 
0.400 0.385 0.324 0.331 0.338 0.254 0.305 0.317 0.302 
Tapped density 
(TBD) g/ml 
0.465 0.451 0.371 0.383 0.399 0.284 0.365 0.379 0.348 
Consolidation 
index 
13.97 14.63 12.66 13.57 15.28 10.56 14.43 16.35 13.21 
Hausner ratio 1.16 1.17 1.14 1.15 1.18 1.11 1.19 1.19 1.16 
Angle of 
repose (Ɵ) 
25.54 25.25 25.18 25.22 24.87 24.85 24.28 26.95 26.11 
 
Post-compression parameters 
Table 3: Evaluation of sustain release matrix tablets 
 
In-vitro dissolution studies 
In-vitro dissolution studies were carried out using USP 
XXIII dissolution apparatus type II at 50 rpm. 
Dissolution test was carried out for a total period of 24 
hr using 0.1N HCl (pH 1.2) solution (900 ml) as a 
dissolution medium at 37 ± 0. 5
º
C for first 2 hr and 
phosphate buffer (pH 6.8) solution (900 ml) solution for 
the rest of the period.5 ml of sample was withdrawn at 
predetermined time interval of 1 hr up to 24 hr and 
replaced with same volume of fresh dissolution medium. 
The withdrawn samples were filtered and analyzed by 
UV spectrophotometer at 376 nm using pH 6.8 as a 
blank. Percentage cumulative drug release was 
calculated. 
 
Table 4: Cumulative % drug release 
Time 
(hrs.) 
% CDR 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 8.6 3.51 3.62 5.09 3.99 3.65 6.8 2.63 2.63 
2 14.41 9.63 8.01 6.91 5.41 4.57 12.46 8.07 5.45 
3 20.11 15.7 12.12 31.75 13.37 13.92 18.16 20.43 7.72 
4 43.78 20.89 15.56 49.29 19.57 17.83 21.63 24.04 10.38 
5 47.71 26.45 19.33 67.12 26.37 21.64 24.4 26.3 13.25 
6 55.72 31.69 22.56 79.98 36.36 26.56 27.68 30.31 17.2 
7 59.83 36.61 26.36 92.17 39.03 31.34 29.91 33.6 23.29 
8 65.47 40.85 29.51 94.11 44.56 35.87 36.76 37.35 29.91 
9 70.31 44.94 32.79 96.49 54.61 38.95 39.78 40.67 38.01 
10 74.95 48.53 36.9 98.47 61.55 42.48 43.87 44.58 46.66 
24 99.81 96.26 67.66 97.36 96.38 82.93 96.97 97.38 97.35 
 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 
Thickness ±S.D. 
mm(n=10) 
2.44 ± 
0.02 
2.50 ± 
0.04 
2.55 ± 
0.03 
2.52 ± 
0.02 
2.45 ± 
0.05 
2.56 ± 
0.03 
2.61 ± 
0.02 
2.62 ± 
0.03 
2.40 ± 
0.04 
Hardness  S.D. 
(kg/cm
2
) 
6.8 ± 
0.3 
7.1 ± 
0.5 
7.2 ± 
0.2 
5.48 ± 
0.2 
5.48 ± 
0.2 
5.7 ±  
0.3 
5.1 ± 
0.5 
5.75 ± 
0.5 
5.64 ± 
0.2 
Average Weight 
variation (n=20) mg 
101.4 ± 
1.51 
102.63 
± 1.69 
101.50 
± 1.41 
100.39 
± 1.35 
101.26± 
1.58 
102.23  
± 1.60 
100.41 
± 1.80 
102.47 
± 1.20 
101.51 
± 1.40 
Drug Content (%) 100.65 
± 1.20 
98.50 ± 
1.46 
97.25 ± 
1.56 
98.70 ± 
0.92 
99.65 ± 
2.12 
98.80 ± 
0.55 
99.50 ± 
0.92 
97.21 ± 
0.83 
101.25 
± 1.31 
Friability (% w/w) 0.38 ± 
0.04 
0.42 ± 
0.06 
0.35 ± 
0.02 
0.45 ± 
0.04 
0.38 ± 
0.08 
0.29 ± 
0.03 
0.36 ± 
0.06 
0.29 ± 
0.09 
0.33 ± 
0.03 
Patil et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2018; 8(2):102-106                   
ISSN: 2250-1177                                                                            [105]                                                                              CODEN (USA): JDDTAO 
 
Figure 1: In-vitro dissolution profile 
Stability studies 
The purpose of stability testing is to provide evidence on 
how the quality of a drug substance or drug product 
varies with time under influence of various 
environmental factors such as temperature, humidity and 
light, and enables recommended storage conditions, 
retest periods and self-lives to be established. 
ICH specifies the length (duration) of study and 
storage conditions 
Accelerated stability studies are testing at 40 
º
C ± 2
 º
C / 
75 % RH ±.5 % for a specific time period up to  3 
months and long term stability studies are testing at 25 
º
C ± 2
 º
C / 60 % RH ±5 % for a specific time period up 
to 12 months. Stability studies were carried out at 40 ± 
2
º
C / 75 % RH for a specific time period up to 90 days. 
 
Table 5: Physicochemical evaluation for stability study 
Parameters Drug 
content 
(%) 
Hardness ± 
S.D. 
(kg/cm
2
 ) 
Friability 
± S.D. 
(% w/w) 
 
Weight 
variation 
(N=20) mg 
In-vitro drug release 
At 10 hr. At 24 hr. 
Initial 99.50 ± 0.92 5.1 ± 0.5 0.36 ± 0.06 100.41 ± 2.80 48.58 96.26 
After one month 99.27 ± 0.45 5.0 ± 0.6 0.36 ± 0.09 100.39 ± 1.35 48.07 96.84 
After two months 99.28 ± 0.42 5.0 ± 0.6 0.36  ± 0.02 100.40 ± 1.12 48.00 96.43 
After three 
months 
99.29 ± 0.68 5.0 ± 0.6 0.36 ± 0.04 100.38 ± 1.24 48.18 96.25 
 
 
Figure 2: FTIR Spectra of F7 after 3 months stability study 
Table 6: position of main functional group bands after three months stability study 
Sample No. -NH 
Stretching 
C=O 
Stretching 
N-H Bending O=S=O Stretching C-H 
(Bend) 
Aromatic 
C-Cl 
Bending 
After 3 
month 
3067.91 1647.88 1595.93 1548.76 1144.49 1383.21 1327.82 829.88 779.36 
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CONCLUSION 
The present investigation demonstrates that, use of 
hydrophilic and hydrophobic polymers could be 
successfully employed for formulating sustained release 
matrix tablets of Lornoxicam. Optimized formulation 
containing HPMC K100M and Ethyl cellulose at 
optimum ratio had successfully sustained the drug 
release for 24 h. Matrix tablets of optimized batch had in 
vitro drug release. It was observed that the optimized 
matrix tablets of optimized batch shows better flow 
property by studying various pre-compression 
parameters. Thus, sustained release matrix tablets of 
Lornoxicam using biocompatible polymers were 
successfully formulated, evaluated and found to be 
suitable candidates in extending the release of the drug 
from the matrix tablets. 
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